Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1984 Aug;74(2):571–580. doi: 10.1172/JCI111454

Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.

R I Levin, P C Harpel, D Weil, T S Chang, D B Rifkin
PMCID: PMC370509  PMID: 6235245

Abstract

Vascular or tissue-type plasminogen activator (TPA) is a key enzyme in physiologic fibrinolysis. To study the role of prostaglandins in modulating the synthesis and release of TPA in vivo, we prospectively studied the effect of aspirin (650 mg/d X 2) on TPA activity in 13 human subjects before and after 10 min of forearm venous occlusion. TPA activity was quantified by a newly developed enzyme-linked immunosorbent assay that both measures and differentiates between TPA and urokinase (UK)-like plasminogen activator activity. This assay is based on the observation that the concentration of alpha 2-plasmin inhibitor-plasmin complexes in Reptilase-clotted plasma increases linearly in proportion to the amount of activator added. Resting TPA activity was higher in women than in men (0.56 +/- 0.59 vs. 0.15 +/- 0.11 U/ml, P = 0.049). Venous occlusion induced an eightfold rise in TPA activity in women (to 4.5 U/ml, P = 0.006) and a 15-fold rise in men (to 2.28 U/ml, P = 0.004), whereas UK activity was not detected. Aspirin inhibited the rise in TPA activity after venous occlusion by 69% in men (P = 0.004) and 70% in women (P = 0.014). In contrast, aspirin had no effect on pre- or post-occlusion hematocrits or Factor VIII-related antigen levels. There was no correlation between plasma salicylate level and percentage inhibition of TPA. Neither exogenous aspirin (0-1 microgram/ml) nor salicylate (0-70 micrograms/ml) inhibited the generation of alpha 2-plasmin inhibitor-plasmin complexes by exogenous TPA or interfered with the assay system. We conclude that aspirin may have an antifibrinolytic effect in man that has not been previously described.

Full text

PDF
571

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brower M. S., Harpel P. C. Alpha-1-antitrypsin-human leukocyte elastase complexes in blood: quantification by an enzyme-linked differential antibody immunosorbent assay and comparison with alpha-2-plasmin inhibitor-plasmin complexes. Blood. 1983 May;61(5):842–849. [PubMed] [Google Scholar]
  2. Camiolo S. M., Thorsen S., Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med. 1971 Oct;138(1):277–280. doi: 10.3181/00379727-138-35878. [DOI] [PubMed] [Google Scholar]
  3. Cash J. D. Effect of moderate exercise on the fibrinolytic system in normal young men and women. Br Med J. 1966 Aug 27;2(5512):502–506. doi: 10.1136/bmj.2.5512.502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980 Jun 18;43(2):77–89. [PubMed] [Google Scholar]
  5. Comp P. C., Esmon C. T. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest. 1981 Nov;68(5):1221–1228. doi: 10.1172/JCI110368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Comp P. C., Jacocks R. M., Ferrell G. L., Esmon C. T. Activation of protein C in vivo. J Clin Invest. 1982 Jul;70(1):127–134. doi: 10.1172/JCI110584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Comp P. C., Jacocks R. M., Rubenstein C., Radcliffe R. A lysine-absorbable plasminogen activator is elevated in conditions associated with increased fibrinolytic activity. J Lab Clin Med. 1981 May;97(5):637–645. [PubMed] [Google Scholar]
  8. Coppe D., Wessinger S. J., Ransil B. J., Harris W., Salzman E. Sex differences in the platelet response to aspirin. Thromb Res. 1981 Jul 1;23(1-2):1–21. doi: 10.1016/0049-3848(81)90233-4. [DOI] [PubMed] [Google Scholar]
  9. Crutchley D. J., Conanan L. B., Maynard J. R. Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandins E1, E2 and I2. J Pharmacol Exp Ther. 1982 Sep;222(3):544–549. [PubMed] [Google Scholar]
  10. Dembinska-Kiec A., Kostka-Trabka E., Gryglewski R. J. Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans. Thromb Haemost. 1982 Apr 30;47(2):190–190. [PubMed] [Google Scholar]
  11. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  12. Elwood P. C., Cochrane A. L., Burr M. L., Sweetnam P. M., Williams G., Welsby E., Hughes S. J., Renton R. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J. 1974 Mar 9;1(5905):436–440. doi: 10.1136/bmj.1.5905.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Elwood P. C., Sweetnam P. M. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979 Dec 22;2(8156-8157):1313–1315. doi: 10.1016/s0140-6736(79)92808-3. [DOI] [PubMed] [Google Scholar]
  14. Ghezzo F., Trinchero P., Pegoraro L. Effects of aspirin treatment upon fibrinolytic activity of peripheral blood granulocytes. Acta Haematol. 1981;65(4):229–232. doi: 10.1159/000207185. [DOI] [PubMed] [Google Scholar]
  15. Harpel P. C. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest. 1981 Jul;68(1):46–55. doi: 10.1172/JCI110253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Harris W. H., Salzman E. W., Athanasoulis C. A., Waltman A. C., DeSanctis R. W. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med. 1977 Dec 8;297(23):1246–1249. doi: 10.1056/NEJM197712082972302. [DOI] [PubMed] [Google Scholar]
  17. Holmberg L., Nilsson I. M., Wallén P., Astedt B. Studies of the blood plasminogen activator induced by 1-desamino-8-D-arginine vasopressin with observations in von Willebrand's disease. Proc Soc Exp Biol Med. 1982 Jun;170(2):126–132. doi: 10.3181/00379727-170-41407. [DOI] [PubMed] [Google Scholar]
  18. Housholder G. T., Moorrees L. L. Fibrinolysis in the rat after short-term aspirin therapy. J Oral Surg. 1980 Jun;38(6):412–416. [PubMed] [Google Scholar]
  19. Hoylaerts M., Rijken D. C., Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912–2919. [PubMed] [Google Scholar]
  20. Jaffe E. A., Hoyer L. W., Nachman R. L. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1973 Nov;52(11):2757–2764. doi: 10.1172/JCI107471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jaffe E. A., Weksler B. B. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest. 1979 Mar;63(3):532–535. doi: 10.1172/JCI109332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. KWAAN H. C., MCFADZEAN A. J. On plasma fibrinolytic activity induced by ischaemia. Clin Sci. 1956 May;15(2):245–257. [PubMed] [Google Scholar]
  23. Keber D., Stegnar M. Exhaustion of arm fibrinolytic potential after repeated venous occlusions and local exercise. Thromb Res. 1982 Dec 15;28(6):693–704. doi: 10.1016/0049-3848(82)90094-9. [DOI] [PubMed] [Google Scholar]
  24. Kelton J. G., Carter C. J., Rosenfeld J., Massicotte-Nolan M. P., Hirsh J. Sex-related differences in the efficacy of acetylsalicylic acid (ASA) : the absorption of ASA and its effect on collagen-induced thromboxane B2 generation. Thromb Res. 1981 Oct 1;24(1-2):163–168. doi: 10.1016/0049-3848(81)90042-6. [DOI] [PubMed] [Google Scholar]
  25. Kelton J. G., Hirsh J., Carter C. J., Buchanan M. R. Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. J Clin Invest. 1978 Oct;62(4):892–895. doi: 10.1172/JCI109203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemost. 1979 Apr 23;41(2):365–383. [PubMed] [Google Scholar]
  27. Korninger C., Collen D. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemost. 1981 Oct;46(3):662–665. [PubMed] [Google Scholar]
  28. Lewis H. D., Jr, Davis J. W., Archibald D. G., Steinke W. E., Smitherman T. C., Doherty J. E., 3rd, Schnaper H. W., LeWinter M. M., Linares E., Pouget J. M. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396–403. doi: 10.1056/NEJM198308183090703. [DOI] [PubMed] [Google Scholar]
  29. Lewis J. G., Pizzo S. V., Adams D. O. Simple and sensitive assay employing stable reagents for quantification of plasminogen activator. Am J Clin Pathol. 1981 Oct;76(4):403–409. doi: 10.1093/ajcp/76.4.403. [DOI] [PubMed] [Google Scholar]
  30. Loskutoff D. J., Edgington T. E. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3903–3907. doi: 10.1073/pnas.74.9.3903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Matsuo O., Rijken D. C., Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemost. 1981 Jun 30;45(3):225–229. [PubMed] [Google Scholar]
  32. Menon I. S. Aspirin and blood fibrinolysis. Lancet. 1970 Feb 14;1(7642):364–364. doi: 10.1016/s0140-6736(70)90747-6. [DOI] [PubMed] [Google Scholar]
  33. Moroi M., Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem. 1976 Oct 10;251(19):5956–5965. [PubMed] [Google Scholar]
  34. Moroz L. A. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med. 1977 Mar 10;296(10):525–529. doi: 10.1056/NEJM197703102961001. [DOI] [PubMed] [Google Scholar]
  35. Nilsson I. M., Robertson B. Effect of venous occlusion on coagulation and fibrinolytic components in normal subjects. Thromb Diath Haemorrh. 1968 Dec 31;20(3):397–408. [PubMed] [Google Scholar]
  36. Ponari O., Manotti C., Poti R., Vaona G., Dettori A. G. Studies on the haemostatic system in peripheral arterial disease. I. Factor VIII, fibrinolytic activity, and changes induced by venous occlusion and nicotinic acid administration. Thromb Res. 1981 Jun 1;22(5-6):565–572. doi: 10.1016/0049-3848(81)90055-4. [DOI] [PubMed] [Google Scholar]
  37. Rijken D. C., Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981 Jul 10;256(13):7035–7041. [PubMed] [Google Scholar]
  38. Rijken D. C., Juhan-Vague I., de Cock F., Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med. 1983 Feb;101(2):274–284. [PubMed] [Google Scholar]
  39. Rijken D. C., Wijngaards G., Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res. 1980 Jun 15;18(6):815–830. doi: 10.1016/0049-3848(80)90204-2. [DOI] [PubMed] [Google Scholar]
  40. Robertson B. R., Pandolfi M., Nilsson I. M. "Fibrinolytic capacity" in healthy volunteers at different ages as studied by standardized venous occlusion of arms and legs. Acta Med Scand. 1972 Mar;191(3):199–202. [PubMed] [Google Scholar]
  41. Rohrlich S. T., Rifkin D. B. Isolation of the major serine protease inhibitor from the 5-day serum-free conditioned medium of human embryonic lung cells and demonstration that it is fetuin. J Cell Physiol. 1981 Oct;109(1):1–15. doi: 10.1002/jcp.1041090102. [DOI] [PubMed] [Google Scholar]
  42. Roth G. J., Stanford N., Majerus P. W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073–3076. doi: 10.1073/pnas.72.8.3073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. SHERRY S., LINDEMEYER R. I., FLETCHER A. P., ALKJAERSIG N. Studies on enhanced fibrinolytic activity in man. J Clin Invest. 1959 May;38(5):810–822. doi: 10.1172/JCI103863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sakata Y., Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest. 1980 Feb;65(2):290–297. doi: 10.1172/JCI109671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sakata Y., Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest. 1982 Mar;69(3):536–542. doi: 10.1172/JCI110479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Serneri G. G., Masotti G., Poggesi L., Galanti G. Release of prostacyclin into the bloodstream and its exhaustion in humans after local blood flow changes (ischemia and venous stasis). Thromb Res. 1980 Jan 1;17(1-2):197–208. doi: 10.1016/0049-3848(80)90306-0. [DOI] [PubMed] [Google Scholar]
  47. Smith J. B., Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971 Jun 23;231(25):235–237. doi: 10.1038/newbio231235a0. [DOI] [PubMed] [Google Scholar]
  48. Tamaki T., Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem. 1982 Dec 25;257(24):14767–14772. [PubMed] [Google Scholar]
  49. Thorsen S., Glas-Greenwalt P., Astrup T. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh. 1972 Aug 31;28(1):65–74. [PubMed] [Google Scholar]
  50. Unkeless J. C., Tobia A., Ossowski L., Quigley J. P., Rifkin D. B., Reich E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses. J Exp Med. 1973 Jan 1;137(1):85–111. doi: 10.1084/jem.137.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Utsunomiya T., Krausz M. M., Valeri C. R., Shepro D., Hechtman H. B. Treatment of pulmonary embolism with prostacyclin. Surgery. 1980 Jul;88(1):25–30. [PubMed] [Google Scholar]
  52. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  53. Vegas A. M., Grindlinger G. A., McLoughlin G. A., Hechtman H. B. Control of pulmonary fibrinolytic activity by prostaglandins. Surg Forum. 1979;30:180–181. [PubMed] [Google Scholar]
  54. Walker I. D., Davidson J. F., Hutton I. "Fibrinolytic potential": the response to a 5 minute venous occlusion test. Thromb Res. 1976 May;8(5):629–638. doi: 10.1016/0049-3848(76)90244-9. [DOI] [PubMed] [Google Scholar]
  55. Weksler B. B., Marcus A. J., Jaffe E. A. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3922–3926. doi: 10.1073/pnas.74.9.3922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Wiman B. Affinity-chromatographic purification of human alpha 2-antiplasmin. Biochem J. 1980 Oct 1;191(1):229–232. doi: 10.1042/bj1910229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Zimmerman R., Thiessen M., Mörl H., Weckesser G. The paradoxical thrombogenic effect of aspirin in experimental thrombosis. Thromb Res. 1979;16(5-6):843–846. doi: 10.1016/0049-3848(79)90228-7. [DOI] [PubMed] [Google Scholar]
  58. Zimmerman T. S., Hoyer L. W., Dickson L., Edgington T. S. Determination of the von Willebrand's disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med. 1975 Jul;86(1):152–159. [PubMed] [Google Scholar]
  59. Zimmermann R., Thiessen M., Walter E., Mörl H. Paradoxical effect of high and low dose aspirin in experimental arterial thrombosis. Artery. 1980;8(5):422–425. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES